Co-diagnostics, inc. reports full year 2024 financial results

Salt lake city , march 27, 2025 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended december 31, 2024. full year 2024 financial results: revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher grant revenue in 2023.
CODX Ratings Summary
CODX Quant Ranking